Artificial liver support systems: what is new over the last decade?

Annals of Intensive Care

Table 5 Studies with clinical endpoints using Prometheus

Study	Years	Design	Patients number	Liver disease	Outcomes	LOE
Sentürk et al. [27]	2010	Uncontrolled, prospective	27	ALF AoCLF	Biochemical improvement Improvement in HE*	3
Kribben et al. [26]	2012	Randomized, controlled, multicentric Prometheus + SMT vs SMT	145	AoCLF	No improvement in 28-day and 90-day survivals, except in subgroup with MELD > 30 Similar adverse effects	1
Bergis et al. [86]	2012	Controlled, non-randomized, multicentric	20	Amanitas phalloides intoxication and liver dysfunction	No statistically significance difference in survivals	2
Komardina et al. [85]	2017	Uncontrolled, prospective	39	Ischaemic ALF	Haemodynamic and biochemical improvements**	3

LOE level of evidence, determined using the strength of recommendation taxonomy (SORT) criteria [50], HE hepatic encephalopathy, SMT standard medical therapy, MLED model for end-stage liver disease
*p < 0.05
**p < 0.01